Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 9/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29529176 | 1.00 | ACMSD (0.84) | ACMSDKMT2ANFE2L2MEN1HPGD | |
| SCHEMBL20137807 | 1.00 | ACMSD (0.84) | ACMSDKMT2ANFE2L2MEN1HPGD | |
| SCHEMBL20068122 | 0.92 | ACMSD (0.74) | ACMSDKMT2AMEN1SMN1; SMN2GAA | |
| SCHEMBL23696631 | 0.92 | ACMSD (0.70) | ACMSDKMT2ANFE2L2POLBGAA | |
| SCHEMBL20137850 | 0.92 | ACMSD (0.74) | ACMSDKMT2AMEN1SMN1; SMN2GAA | |
| SCHEMBL29529412 | 0.91 | ACMSD (1.00) | ACMSDKMT2ANFE2L2MEN1HPGD | |
| SCHEMBL20137829 | 0.91 | ACMSD (1.00) | ACMSDKMT2ANFE2L2MEN1HPGD | |
| SCHEMBL20068024 | 0.91 | ACMSD (1.00) | ACMSDKMT2ANFE2L2MEN1HPGD | |
| SCHEMBL20137869 | 0.91 | ACMSD (0.70) | ACMSDKMT2ANFE2L2POLB | |
| SCHEMBL20068065 | 0.91 | ACMSD (0.70) | ACMSDKMT2ANFE2L2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210230123-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2021-07-29 | — | — | US | claimed |
| EP-3526199-B1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S R L (IT) | 2022-04-13 | — | — | EP | disclosed |
| US-20210230123-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2021-07-29 | — | — | US | disclosed |
| US-20210230123-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2021-07-29 | — | — | US | disclosed |
| US-20180134667-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2018-05-17 | — | — | US | disclosed |
| US-20180134667-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2018-05-17 | — | — | US | disclosed |
| WO-2018069532-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230123-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | ACMSD, GLS, ALDH7A1 | ACMSD 1/4885KMT2A 1353/4885NFE2L2 634/4885 |
| US-20180134667-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | ACMSD, GLS, ALDH7A1 | ACMSD 1/4885KMT2A 1353/4885NFE2L2 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.